Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 1998

View Archived Issues

Cambridge NeuroScience: Q3 1998 highlights

Pharming: Q3 and nine-month highlights

Centocor: clinical development program update

Vertex reports preliminary data on Incel in soft tissue carcinoma and initiates new phase II trial

Abbott obtains license to market Nyotran

New U.S. patent provides protection for improved Avicine formulations

Intellivax presents promising phase I data for intranasal vaccine for shigellosis

DBO-83: novel nicotinic agonist with antiamnestic activity

Zeneca files sNDA for Accolate asthma therapy

Antihyperalgesic effects of SB-235863 presented at Society for Neuroscience meeting

Nortran enters collaborative agreement with Astra

New warnings issued for Tasmar; E.U. suspends use

Picornavirus protease inhibitors from Agouron especially useful for rhinovirus infections

Clarion prepares novel compounds for cancer, psoriasis and inflammation

Erythromycin derivatives with high activity against sensitive and resistant microorganisms

Antitumor tetramic acid compound produced by Streptomyces

Dual NK1 and NK2 receptor antagonists under study at Sankyo for respiratory disorders, incontinence

Ligand reports design of new nonsteroidal human progesterone agonists

Discovery of potent, nontoxic, orally active ACAT inhibitors reported by Fujisawa

Parke-Davis identifies potent inhibitor of PDGF receptor TK and PDGF-dependent tumor growth

New oral HRT option approved by FDA

SangCya launched in U.S. less than three weeks following approval

Latanoprost monotherapy is as effective as combination therapy in lowering IOP

Imutec changes name to Lorus Therapeutics; achievements highlighted

Thalidomide analogue CC-1069 shows potent antiarthritic activity in rat model

Gastrimmune enters phase III trials for pancreatic cancer

Celgene describes SelCID compounds for treatment of CHF

Meridian completes Gull Laboratories acquisition

Neuroprotective effects and mode of action of Ono-2506 detailed at recent meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...